Liver cancer, TNBC (ER+ subtype, BRACA1/2 mutant TNBC), epigenetically driven prostate cancer with AR-dependent pathways, BRCA1/2, EZH2 dysregulation, IDH1/2 mutant glioblastoma, with histone modifications. This evidence concerns the gene EZH2 and prostate carcinoma.